Healthcare Providers and Services
Company Overview of National Institutes of Health
National Institutes of Health operates as a medical research agency in the United States. It offers services for conducting and supporting basic, clinical, and translational medical research; and investigates the causes, treatments, and cures for common and rare diseases. The company also provides leadership and direction to programs designed to improve the health by conducting and supporting research in the causes, diagnosis, prevention, and cure of human diseases; in the processes of human growth and development; in the biological effects of environmental contaminants; in the understanding of mental, addictive, and physical disorders; and in directing programs for the collection, dissemina...
9000 Rockville Pike
Bethesda, MD 20892
Founded in 1887
Key Executives for National Institutes of Health
Chief Financial Officer and Deputy Director of Management
Chief Information Officer
Deputy Director of Extramural Research
Deputy Director of Intramural Research
Compensation as of Fiscal Year 2014.
National Institutes of Health Key Developments
National Institutes of Health Presents at BioFlorida Annual Conference, Oct-13-2014 11:30 AM
Oct 11 14
National Institutes of Health Presents at BioFlorida Annual Conference, Oct-13-2014 11:30 AM. Venue: Harbor Beach Marriott, Ft. Lauderdale, Florida, United States. Speakers: Sitta Sittapalam, Senior Scientific Officer & Project Manager.
Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens
Sep 18 14
Spring Bank Pharmaceuticals, Inc. announced a research collaboration with the National Institutes of Health (NIH) for animal testing of the Company's lead compound, SB 9200, against multiple viral pathogens, classified as "Special Pathogens," against which currently there are no effective antiviral therapies. SB 9200, derived from Spring Bank's proprietary Small Molecule Nucleic Acid Hybrid (SMNH) technology platform, is a novel, broad-spectrum anti-viral agent that uniquely acts by selectively modulating the host immune response to viral infections. SB 9200 has recently completed a Phase 1b clinical trial for treatment of Hepatitis C (HCV) and is also being developed for the treatment of Hepatitis B Virus (HBV) and Respiratory Syncytial Virus (RSV).
National Institutes of Health to Launch Human Safety Study of Ebola Vaccine Candidate
Aug 28 14
National Institutes of Health announced Initial human testing of an investigational vaccine to prevent Ebola virus disease will begin next week by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The early-stage trial will begin initial human testing of a vaccine co-developed by NIAID and GlaxoSmithKline (GSK) and will evaluate the experimental vaccines safety and ability to generate an immune system response in healthy adults. Testing will take place at the NIH Clinical Center in Bethesda, Maryland. The study is the first of several Phase 1 clinical trials that will examine the investigational NIAID/GSK Ebola vaccine and an experimental Ebola vaccine developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corp. The others are to launch in the fall. These trials are conducted in healthy adults who are not infected with Ebola virus to determine if the vaccine is safe and induces an adequate immune response. In parallel, NIH has partnered with a British-based international consortium that includes the Wellcome Trust and Britains Medical Research Council and Department for International Development to test the NIAID/GSK vaccine candidate among healthy volunteers in the United Kingdom and in the West African countries of Gambia (after approval from the relevant authorities) and Mali. Additionally, the U.S. Centers for Disease Control and Prevention has initiated discussions with Ministry of Health officials in Nigeria about the prospects for conducting a Phase 1 safety study of the vaccine among healthy adults in that country. The pace of human safety testing for experimental Ebola vaccines has been expedited in response to the ongoing Ebola virus outbreak in West Africa. According to the World Health Organization (WHO), more than 1,400 suspected and confirmed deaths from Ebola infection have been reported in Guinea, Liberia, Nigeria, and Sierra Leone since the outbreak was first reported in March 2014. There is an urgent need for a protective Ebola vaccine, and it is important to establish that a vaccine is safe and spurs the immune system to react in a way necessary to protect against infection.
Similar Private Companies By Industry
Recent Private Companies Transactions